GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) shareholders are probably feeling a little disappointed, since its shares fell 2.2% to ₹2,570 in the week after its latest quarterly results. Results overall were respectable, with statutory earnings of ₹14.00 per share roughly in line with what the analysts had forecast. Revenues of ₹9.4b came in 3.0% ahead of analyst predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the current consensus from GlaxoSmithKline Pharmaceuticals' four analysts is for revenues of ₹42.5b in 2027. This would reflect a modest 7.5% increase on its revenue over the past 12 months. Per-share earnings are expected to rise 8.7% to ₹68.53. Before this earnings report, the analysts had been forecasting revenues of ₹42.0b and earnings per share (EPS) of ₹67.90 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
Check out our latest analysis for GlaxoSmithKline Pharmaceuticals
It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹3,081. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values GlaxoSmithKline Pharmaceuticals at ₹3,504 per share, while the most bearish prices it at ₹2,874. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that GlaxoSmithKline Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 10% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 3.4% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. GlaxoSmithKline Pharmaceuticals is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ₹3,081, with the latest estimates not enough to have an impact on their price targets.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple GlaxoSmithKline Pharmaceuticals analysts - going out to 2028, and you can see them free on our platform here.
Even so, be aware that GlaxoSmithKline Pharmaceuticals is showing 1 warning sign in our investment analysis , you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.